PDCD1 and lung carcinoma: Both luteolin and apigenin significantly inhibit the proliferation of KRAS-mutant lung cancer cells and downregulate IFN-γ-induced PD-L1 expression, showing synergistic effects when combined with PD-1 inhibitors.